Protein / target
B-lymphocyte antigen CD20
Protein at a glance
Biological role
Epidermal growth factor receptor binding
Primary system
Immune system
Strongest disease association
B-cell chronic lymphocytic leukemia
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
11 approved · 7 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes (PubMed:12920111, PubMed:3925015, PubMed:7684739). Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR (PubMed:12920111, PubMed:18474602, PubMed:7684739)
Subcellular location
Domains and Gene Ontology detail (20)Hide
Gene Ontology
- Ccell surface
- Cexternal side of plasma membrane
- Cextracellular exosome
- Cextracellular space
- Cplasma membrane
- Cplasma membrane raft
- Fepidermal growth factor receptor binding
- Fidentical protein binding
- Fimmunoglobulin binding
- FMHC class II protein complex binding
- PB cell activation
- PB cell differentiation
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·B cell activation
- ·B cell differentiation
- ·B cell proliferation
- ·B cell receptor signaling pathway
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
B-lymphocyte antigen CD20 binding agent
Appears in clinical studies involving multiple sclerosis, diffuse large B-cell lymphoma, relapsing-remitting multiple sclerosis, chronic progressive multiple sclerosis
B-lymphocyte antigen CD20 binding agent
Appears in clinical studies involving follicular lymphoma, B-cell chronic lymphocytic leukemia, B-cell chronic lymphocytic leukemia, B-cell chronic lymphocytic leukemia
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 462 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 18 total
diffuse large B-cell lymphoma · neoplasm · diffuse large B-cell lymphoma
follicular lymphoma · B-cell chronic lymphocytic leukemia · B-cell chronic lymphocytic leukemia
multiple sclerosis · relapsing-remitting multiple sclerosis · chronic progressive multiple sclerosis
follicular lymphoma · follicular lymphoma · non-Hodgkin lymphoma
B-cell chronic lymphocytic leukemia · B-cell chronic lymphocytic leukemia · non-Hodgkin lymphoma
diffuse large B-cell lymphoma · non-Hodgkin lymphoma · non-Hodgkin lymphoma
follicular lymphoma · neoplasm · high grade B-cell lymphoma
non-Hodgkin lymphoma · follicular lymphoma · follicular lymphoma
non-Hodgkin lymphoma · follicular lymphoma · non-Hodgkin lymphoma
follicular lymphoma · B-cell non-Hodgkin lymphoma · diffuse large B-cell lymphoma
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Trial status changed
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- New publicationEffects of different B-cell-depleting strategies on the lymphatic tissue.
- Regulatory approval
Approval: Ocrevus (EMA)
- New publicationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
- New publicationOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
- Regulatory approval
Approval: Gazyvaro (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.